Navigation Links
Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
Date:9/30/2008

rams, and ability to develop novel medicines in the areas of hepatitis C and oncology. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. For example, the results of preclinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 and ANA773 will not have unforeseen safety issues, will have favorable results in future clinical trials or will receive regulatory approval. Risk factors that may cause actual results to differ are discussed in Anadys' SEC filings, including Anadys' Form 10-K for the year ended December 31, 2007 and Anadys' Form 10-Q for the quarter ended June 30, 2008. All forward-looking statements are qualified in their entirety by this cautionary statement. Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.


'/>"/>
SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
2. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
3. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
4. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
5. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
6. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
7. Potentia Pharmaceuticals Announces Positive Safety Data and Study Expansion in Phase I Trial for Lead Drug Candidate POT-4
8. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
9. Lotus Pharmaceuticals, Inc.s New Drug Laevo-Bambutero Begins Evaluation for Clinical Trials
10. VIA Pharmaceuticals Completes Patient Visits in Phase 2 Acute Coronary Syndrome (ACS) Trial
11. QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... DUBLIN , August 22, 2014 ... of Hospital TVs Today Lincor announced general ... Patient Engagement solution that delivers a range of education, ... sets.      (Logo: http://photos.prnewswire.com/prnh/20140822/702945) , ... in defining point of care patient engagement to bedside ...
(Date:8/22/2014)... Aug. 22, 2014  Landauer, Inc. (NYSE: ... radiation measurement and monitoring, outsourced medical physics services and ... William E. Saxelby , its President and Chief Executive ... Executive Officer and as a member of the Board ... will be replaced on an interim basis by ...
(Date:8/22/2014)... , Aug. 22, 2014  WaferGen Bio-systems, Inc. (NASDAQ: ... offering of units of common stock and warrants at ... of $20 million, prior to deducting underwriting discounts and ... shares and warrants are immediately separable and will be ... to begin trading on The NASDAQ Stock Market under ...
Breaking Medicine Technology:Lincor Unveils Next Generation TV-based Patient Engagement Solution 2Landauer, Inc. Announces Executive Management Change 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 4
... MONMOUTH JUNCTION, N.J., March 29, 2011 Tris Pharma, ... anticipated re-launch of the MyKidz® Iron product ... has attracted a loyal following of pediatricians, pediatric nurses ... its product pipeline in a different direction, availability of ...
... NEW YORK, March 29, 2011 Reportlinker.com announces that a ... Top 150 Antibiotic Manufacturers (Global) ... Industry Report Plimsoll Publishing Ltd. Do ... in the industry? Which company has the highest ...
Cached Medicine Technology:Tris Pharma Announces Availability of the MyKidz® Iron Product Line - the Best Tasting Iron Supplements 2Tris Pharma Announces Availability of the MyKidz® Iron Product Line - the Best Tasting Iron Supplements 3Reportlinker Adds Top 150 Antibiotic Manufacturers (Global) 2Reportlinker Adds Top 150 Antibiotic Manufacturers (Global) 3Reportlinker Adds Top 150 Antibiotic Manufacturers (Global) 4
(Date:8/23/2014)... Teen substance abuse ranks as one of the most ... adolescents throughout North Carolina struggle with a drug or alcohol ... professional rehab due to a lack of information available to ... Teens Holly Springs is a helpline designed to make a ... abusers in Wake County who are seeking to overcome ...
(Date:8/22/2014)... August 23, 2014 2014 Deep ... a professional and in-depth research report on the ... Meter information, including Glucose Meter definition, classification, application, ... overview. This research covers the international market analysis, ... analysis covering macroeconomic environment & economic situation analysis. ...
(Date:8/22/2014)... August 22, 2014 AWeber, one ... that currently helps more than 120,000 small businesses ... the attention of Shane Michaels, prompting an investigative review. ... element for any online marketing campaign, despite what some ... the marketing world,” reports Michaels. “AWeber is a great ...
(Date:8/22/2014)... This report studies the "Sample Preparation Market by ... Kits (Isolation, Purification), By Application (Genomics, Proteomics), by ... 2018" This market was valued at $4,254.8 million ... a CAGR of 5.9% from 2013 to 2018, ... 98 market data Tables and 23 Figures spread ...
(Date:8/22/2014)... Millennium Treatment Group has recently noticed an ... level of drug use among teenagers. The treatment facility aims ... and work to minimize drug abuse. , America is currently ... addiction in history. According to the National Institute of ... aged 12 or older—or 9.2 percent of the population—had used ...
Breaking Medicine News(10 mins):Health News:New Helpline Provides Teen Drug & Alcohol Recovery Information in Holly Springs, NC 2Health News:Glucose Meter Industry Global (Europe, Asia, NA, ROW) Analysis Now Available at ReportsnReports.com 2Health News:Glucose Meter Industry Global (Europe, Asia, NA, ROW) Analysis Now Available at ReportsnReports.com 3Health News:AWeber: Review Exposes Affordable Provider of Opt-In Email Marketing Services 2Health News:Sample Preparation Market by Product and Application Worth $5,672 Million by 2018 - New Research Report by MarketsandMarkets 2Health News:Sample Preparation Market by Product and Application Worth $5,672 Million by 2018 - New Research Report by MarketsandMarkets 3Health News:Sample Preparation Market by Product and Application Worth $5,672 Million by 2018 - New Research Report by MarketsandMarkets 4Health News:Millennium Treatment Group Sees Increase in Marijuana Use Among Youth 2
... management solutions , today announced that Premier Inc. has selected ... , ... Jacksonville, FL (PRWEB) July ... compensation management solutions , today announced that Premier Inc. has ...
... years of education, completing specialized training and practicing medicine in fields ... College at Indiana University of Pennsylvania influence and enhance their chosen ... ... (PRWEB) July 16, 2008 -- Each day brings patients with different ...
... VendorClear™, the company who pioneered web-based vendor access services for ... and vendor representatives operate more efficiently and increase facility safety. ... ... July 16, 2008 -- VendorClear™, the company who pioneered web-based ...
... health professionals from across the country will convene July ... and policy issues faced by public health officials and ... , "Confronting the Ethics of Pandemic Influenza Planning: ... the Indiana State Department of Health, the Indiana University ...
... in America for Over 26,Million Americans Suffering from ... WASHINGTON, July 15 In response to today,s,passage ... Partners (KCP) -- an,alliance of patient advocates, dialysis ... quality of care for individuals,with kidney disease and ...
... Quality through National E-Prescribing, ... AARP ... DESKS: AARP,is recording House and Senate roll call votes on key issues ... results,of these key votes., , SUMMARY: Today the U.S. House of ...
Cached Medicine News:Health News:Premier Inc Automates their Compensation Management Processes, Chooses HCR Software's CompensationXL Product 2Health News:Premier Inc Automates their Compensation Management Processes, Chooses HCR Software's CompensationXL Product 3Health News:Premier Inc Automates their Compensation Management Processes, Chooses HCR Software's CompensationXL Product 4Health News:Robert E Cook Honors College Women In Medicine 2Health News:Robert E Cook Honors College Women In Medicine 3Health News:Robert E Cook Honors College Women In Medicine 4Health News:Robert E Cook Honors College Women In Medicine 5Health News:Robert E Cook Honors College Women In Medicine 6Health News:VendorClear™ Introduces Revolutionary Products for Healthcare Facilities and Vendor Representatives 2Health News:Confronting Ethics of Pandemic Influenza Planning: 2008 Summit of the States 2Health News:Kidney Community Thanks Congress for Passing Landmark End Stage Renal Disease (ESRD) Reform 2Health News:AARP Thanks Congress for Keeping Medicare Fair, Overriding White House Veto 2Health News:AARP Thanks Congress for Keeping Medicare Fair, Overriding White House Veto 3
Fluoroperm 151 lens meets special needs of certain patients who need exceptional oxygen permeability for specific corneal condition or lifestyle requirements....
... Thinsite is designed using sophisticated lathing ... concepts. Thinsite lenses feature a center thickness ... ranges. While all plus powered Thinsite lenses ... over standard designs. The unique design eliminates ...
An easy-to-fit RGP daily wear lens with a unique bi-aspheric back surface design that provides excellent patient comfort and adaptation. Boston Envision contact lenses are an ideal alternative for vi...
Ophthalmic surgery stretcher. Designed for exceptional surgeon access, ideal for either superior or temporal approach....
Medicine Products: